Intestinal Disease Articles & Analysis
13 news found
Klebsiella is described by the Centers for Disease Control and Prevention (CDC) as a type of gram-negative bacteria that can cause different types of healthcare-associated infections (HAIs). ...
The Centers for Disease Control and Prevention (CDC) describes Klebsiella as a type of gram-negative bacteria that can cause different types of healthcare-associated infections (HAIs). ...
An article published last year in Emerging Infectious Diseases detailed a notable increase of carbapenem-resistant Klebsiella pneumoniae (CRKP) infections in New York City during 2021 through June of 2022. The data for the study came from a large public healthcare system in New York City that serves more than 1.2 million people each year. The Centers for ...
With locations in the US and Europe, today MatTek's offerings include skin, eye, oral, respiratory, vaginal, and intestinal tissue models including disease modeling, validated, and custom testing services, multiple donor primary cells, culture media, and highly optical cultureware. ...
With locations in the US and Europe, today MatTek's offerings include skin, eye, oral, respiratory, vaginal, and intestinal tissue models including disease modeling, validated, and custom testing services, multiple donor primary cells, culture media, and highly optical cultureware. ...
In recent years, the analysis of viral nucleic acid sequences in the intestine by high-throughput sequencing technology has revealed a dynamic and diverse enterovirome. ...
The study synthesizes multiple streams of existing evidence from molecular biology through clinical observations to build a new paradigm for understanding the role of the small intestine in metabolic disease. The company believes the Metabolic Balance Model is one of the most comprehensive frameworks in this field. ...
It will evaluate the efficacy of Revita DMR (duodenal mucosal resurfacing), a first-in-class intervention targeting the role of the intestine in metabolic disease. The trial’s primary endpoint is the percentage of patients who are able to achieve target glycemic control (HbA1c less than or equal to 7%) without the need for insulin at 24 weeks, comparing ...
LUCENT-2, a multicenter, randomized, double-blind, placebo-controlled maintenance study of mirikizumab in patients who have completed the 12-week LUCENT-1 induction study is ongoing. UC is a chronic inflammatory disease of the large intestine, also referred to as the colon, that affects the lining of the colon and may cause small sores, or ulcers, to form.i This ...
Under the fibroblast cells category, 175 types of cells are provided, including human cardiac fibroblasts, human dermal fibroblasts, Human Esophageal Fibroblasts, Human Intestinal Fibroblasts, Adult Dermal Fibroblasts, some diseased fibroblasts like diseased human lung fibroblasts and so on, besides with the listed cells, custom needs regarding ...
” Gastroparesis is a disorder that slows or stops the movement of food from the stomach to the small intestine when muscles in the stomach are not contracting properly. It is caused by damage to the vagus nerve that controls the muscles of the stomach and small intestine, often as a result of intestinal surgery, neurological ...
Spore crops grown using the test method (soon to be published as E3011, Test Method for in vitro Production of Clostridium Difficile Spores) will be used in laboratories to test the efficacy of drugs that fight C. difficile, a source of infectious intestinal diseases such as colitis. Subcommittee E35.15 on Antimicrobial Agents invites all interested parties to ...
C. difficile-associated diarrhea ranges from mild to severe and can sometimes result in severe inflammation of the intestines. The C. difficile organism can be found in feces, and is transferred from infected patients or contaminated environmental surfaces to patients via the hands of hospital personnel. ...